Barclays’s ANI Pharmaceuticals ANIP Stock Holding History

Barclays’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$14K	–	6914
2019 Q1	$14K	Sell	200 -2,500	-93%	-$147K	﹤0.01%	6461
2018 Q4	$122K	Sell	2,700 -1,200	-31%	-$62.9K	﹤0.01%	4910
2018 Q3	$221K	Buy	3,900 +3,500	+875%	+$214K	﹤0.01%	4919
2018 Q2	$27K	Sell	400 -5,800	-94%	-$362K	﹤0.01%	6012
2018 Q1	$361K	Buy	+6,200	New	+$394K	﹤0.01%	4283
2017 Q3	–	Sell	-2,000	Closed	-$94K	–	6823
2017 Q2	$94K	Hold	2,000	–	–	﹤0.01%	4950
2017 Q1	$99K	Buy	+2,000	New	+$112K	﹤0.01%	4881
2014 Q1	–	Sell	-976	Closed	-$20K	–	7557
2013 Q4	$20K	Hold	976	–	–	﹤0.01%	6714
2013 Q3	$9K	Sell	976 -257	-21%	-$1.85K	﹤0.01%	6818
2013 Q2	$7K	Buy	+1,233	New	+$8.63K	﹤0.01%	7247

Other funds holding ANIP

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Dana Investment Advisors Waukesha, Wisconsin $3.69B AUM 30.1% 1-Year Est. Return

Barclays's ANIP Position: Q3 2026 in Review

Barclays increased its ANI Pharmaceuticals (ANIP) stake by 3.5% in Q3 2026, buying an estimated $321K and bringing the position to 123,878 shares worth $9M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Barclays first reported a position in ANIP in Q2 2013 and has held it in 54 quarters since. The position peaked at $12M in Q2 2025. 112 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

Barclays held 123,878 shares of ANI Pharmaceuticals worth $9M as of Q3 2026.
Barclays bought 4,171 ANI Pharmaceuticals shares in Q3 2026, an estimated $321K.
ANI Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1701 holding.
Barclays first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
Barclays's ANI Pharmaceuticals position peaked at $12M in Q2 2025.
112 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.